Patient’s Name
Today’s Date
ℹTo save a PDF:
Click "Print", and select "Print to PDF"
Click "Print", and select "Print to PDF"
COMPERA 2.0: 4-Strata Risk Assessment
The 2022 ESC/ERS Treatment Guidelines recommend using 4-strata risk stratification in follow-up visits every 3-6 months. All values are required to calculate score. 1 year transplant-free mortality risk is based on average points assigned.
Risk Status
(1 Yr Survival Rates)
Points Assigned
(1 Yr Survival Rates)
Points Assigned
Low
(98.5%)
1
(98.5%)
1
Intermediate-Low
(97.2%)
2
(97.2%)
2
Intermediate-High
(91.3%)
3
(91.3%)
3
High
(78%)
4
(78%)
4
Functional
Class
6-Minute
Walk Test
NT-proBNP/
BNP
Risk Score
Low Risk
Intermediate-
Low Risk
Low Risk
Intermediate-
High Risk
High Risk
High Risk
All use subject to terms and conditions at www.unither.com/terms.html
References:1.Boucly A, Weatherald J, Salvale L, et al. External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry. Eur Respir J 2022; 59:2102419 [DOI: 10.1183/13993003.02419-2021].
Sponsored by United Therapeutics
Committed to Improving the Lives of Patients
©2023 United Therapeutics Corporation. All rights reserved. US-DS-1064